RE:AWARE-1 data analyzed showing Pelareorep priming of TMEAWARE-1's patients were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab (Tecentriq®) prior to surgery.
Pelareorep treatment in cohort 1 upregulated tumor PD-L1 expression, induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased the CelTIL score, a measure of tumor cellularity and inflammation associated with favorable clinical outcomes. These desired outcomes were further enhanced in cohort 2 patients, demonstrating pelareorep and atezolizumab synergistically combine to generate an anti-cancer immune response in the tumor and peripheral blood. Notably, cohort 2 met the pre-specified success criteria for the study's primary endpoint (50% of patients with ≥ 30% increase in CelTIL score), with six of ten patients achieving at least a 30% increase in CelTIL score following treatment.
https://www.newswire.ca/news-releases/oncolytics-biotech-r-and-solti-achieve-primary-endpoint-in-aware-1-study-871181269.html
To understand the complex tumor microenvironment (TME) and immune responses in patients before and after treatment, imaging mass cytometry (IMC) was used to perform single cell, highly multiplexed, analysis of their tissue samples.
In accordance with the prior AWARE-1 results, IMC demonstrated an enhanced immune state of the tumors after treatment.
Results confirm previous data from the window of opportunity AWARE-1 study demonstrating synergy between pelareorep in combination with atezolizumab, and a favorable immunologic response in tumors from early breast cancer (eBC) patients.
https://jitc.bmj.com/content/11/Suppl_1/662